Terms: = Colorectal cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Treatment
578 results:
1. A metal-organic nanoframework for efficient colorectal cancer immunotherapy by the cGAS-STING pathway activation and immune checkpoint blockade.
Zhang X; Tian H; Chen Y; Liang B; Nice EC; Huang C; Xie N; Zheng S
J Nanobiotechnology; 2024 Sep; 22(1):592. PubMed ID: 39343911
[TBL] [Abstract] [Full Text] [Related]
2. USP18 Is Associated with pd-l1 Antitumor Immunity and Improved Prognosis in colorectal cancer.
Jifu C; Lu L; Ding J; Lv M; Xia J; Wang J; Wang P
Biomolecules; 2024 Sep; 14(9):. PubMed ID: 39334957
[TBL] [Abstract] [Full Text] [Related]
3. A Multifunctional Biomimetic Nanoplatform for Dual Tumor Targeting-Assisted Multimodal Therapy of Colon cancer.
Wan X; Zhang Y; Wan Y; Xiong M; Xie A; Liang Y; Wan H
ACS Nano; 2024 Oct; 18(39):26666-26689. PubMed ID: 39300799
[TBL] [Abstract] [Full Text] [Related]
4. Identification of PFKFB3 as a key factor in the development of colorectal cancer and immunotherapy resistance.
Lu S; Zhao R; Han Y; Shao S; Ji Y; Zhang J; Pan H; Sun J; Feng Y
Clin Exp Med; 2024 Sep; 24(1):219. PubMed ID: 39261380
[TBL] [Abstract] [Full Text] [Related]
5. Neoadjuvant envafolimab in a patient with MSI-H/dMMR colon cancer: a case report and literature review.
Chen Z; Zhou J; Chen W; Wu T; Lian K; Shen T
Immunotherapy; 2024; 16(10):649-657. PubMed ID: 39259508
[TBL] [Abstract] [Full Text] [Related]
6. GSH-responsive polymeric micelles-based augmented photoimmunotherapy synergized with PD-1 blockade for eliciting robust antitumor immunity against colon tumor.
Huang C; Yang X; Li H; Zhang L; Guo Q; Yu Q; Wang H; Zhang L; Zhu D
J Nanobiotechnology; 2024 Sep; 22(1):542. PubMed ID: 39238020
[TBL] [Abstract] [Full Text] [Related]
7. Immunotherapy in Gastrointestinal cancers.
Lote H; Chau I
Cancer Treat Res; 2024; 192():277-303. PubMed ID: 39212926
[TBL] [Abstract] [Full Text] [Related]
8. The prognostic value of programmed death-ligand 1 (pd-l1) expression in resected colorectal cancer without neoadjuvant therapy - differences between antibody clones and cell types.
Nobin H; Garvin S; Hagman H; Nodin B; Jirström K; Brunnström H
BMC Cancer; 2024 Aug; 24(1):1051. PubMed ID: 39187798
[TBL] [Abstract] [Full Text] [Related]
9. Effects of Degreasing Pretreatment on Immunohistochemistry and Molecular Analysis of Gastrointestinal and Breast cancer Samples.
Jin S; Wu D; Zhang Y; Tang H; Yu J; Zhang J; Li X; Liu Y; Yang J; Zhang T; Hu M; Li X; Xiao S; Yue J; Wang M
Lab Invest; 2024 Sep; 104(9):102125. PubMed ID: 39168250
[TBL] [Abstract] [Full Text] [Related]
10. Jianpi Jiedu Recipe Inhibits Proliferation through Reactive Oxygen Species-Induced Incomplete Autophagy and Reduces pd-l1 Expression in Colon cancer.
Cheng L; Xu L; Yuan H; Zhao Q; Yue W; Ma S; Wu X; Gu D; Sun Y; Shi H; Xu J
Integr Cancer Ther; 2024; 23():15347354241268064. PubMed ID: 39155544
[TBL] [Abstract] [Full Text] [Related]
11. Urachal and Nonurachal Adenocarcinomas of the Urinary Bladder: A Comprehensive Genomic Profiling Study.
Cigliola A; Basnet A; Jacob JM; Mercinelli C; Tateo V; Patanè DA; Bratslavsky G; Cheng L; Grivas P; Kamat AM; Spiess PE; Pavlick DC; Lin DI; Ross JS; Necchi A
JCO Precis Oncol; 2024 Aug; 8():e2400200. PubMed ID: 39151108
[TBL] [Abstract] [Full Text] [Related]
12. Nilotinib boosts the efficacy of anti-pdl1 therapy in colorectal cancer by restoring the expression of MHC-I.
Dong H; Wen C; He L; Zhang J; Xiang N; Liang L; Hu L; Li W; Liu J; Shi M; Hu Y; Chen S; Liu H; Yang X
J Transl Med; 2024 Aug; 22(1):769. PubMed ID: 39143573
[TBL] [Abstract] [Full Text] [Related]
13. Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a pd-l1-dependent CD28 costimulator and dual pd-l1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab.
Cavalcante L; Chandana S; Lakhani N; Enstrom A; LeBlanc H; Schmalz J; Lengyel K; Schneider F; Thomas H; Chisamore MJ; Peng SL; Naumovski A; Davar D
J Immunother Cancer; 2024 Aug; 12(8):. PubMed ID: 39142718
[TBL] [Abstract] [Full Text] [Related]
14. Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial.
Raghav K; Siena S; Takashima A; Kato T; Van den Eynde M; Pietrantonio F; Komatsu Y; Kawakami H; Peeters M; Andre T; Lonardi S; Yamaguchi K; Tie J; Castro CG; Hsu HC; Strickler JH; Kim TY; Cha Y; Barrios D; Yan Q; Kamio T; Kobayashi K; Boran A; Koga M; Allard JD; Yoshino T
Lancet Oncol; 2024 Sep; 25(9):1147-1162. PubMed ID: 39116902
[TBL] [Abstract] [Full Text] [Related]
15. Dual PI3K/mTOR Inhibitor BEZ235 combined with BMS-1166 Promoting Apoptosis in colorectal cancer.
Liu X; Xu W; Li L; Zhang Z; Lu M; Xia X
Int J Med Sci; 2024; 21(10):1814-1823. PubMed ID: 39113885
[No Abstract] [Full Text] [Related]
16. Clinicopathological and immune characterization of mismatch repair deficient endocervical adenocarcinoma.
Wu YW; Wei LJ; Yang X; Liang HY; Cai MY; Luo RZ; Liu LL
Oncologist; 2024 Oct; 29(10):e1302-e1314. PubMed ID: 39110901
[TBL] [Abstract] [Full Text] [Related]
17. Phase I studies of davoceticept (ALPN-202), a pd-l1-dependent CD28 co-stimulator and dual pd-l1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2).
Davar D; Cavalcante L; Lakhani N; Moser J; Millward M; McKean M; Voskoboynik M; Sanborn RE; Grewal JS; Narayan A; Patnaik A; Gainor JF; Sznol M; Enstrom A; Blanchfield L; LeBlanc H; Thomas H; Chisamore MJ; Peng SL; Naumovski A
J Immunother Cancer; 2024 Aug; 12(8):. PubMed ID: 39097413
[TBL] [Abstract] [Full Text] [Related]
18. Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial.
Xiao WW; Chen G; Gao YH; Lin JZ; Wu XJ; Luo HL; Lu ZH; Wang QX; Sun R; Cai PQ; Zhu CM; Liu M; Li JB; Wang YR; Jin Y; Wang F; Luo HT; Li CL; Pan ZZ; Xu RH
Cancer Cell; 2024 Sep; 42(9):1570-1581.e4. PubMed ID: 39094560
[TBL] [Abstract] [Full Text] [Related]
19. The aminophospholipid transporter, ATP8B3, as a potential biomarker and target for enhancing the therapeutic effect of pd-l1 blockade in colon adenocarcinoma.
Zhang W; Xie Y; Liu Z; Zhang J; Ni B; Gao W; Xing W; Zhou Y; Si T
Genomics; 2024 Sep; 116(5):110907. PubMed ID: 39074670
[TBL] [Abstract] [Full Text] [Related]
20. The long-term effectiveness and mechanism of oncolytic virotherapy combined with anti-pd-l1 antibody in colorectal cancer patient.
Zhang H; Ren Y; Wang F; Tu X; Tong Z; Liu L; Zheng Y; Zhao P; Cheng J; Li J; Fang W; Liu X
Cancer Gene Ther; 2024 Sep; 31(9):1412-1426. PubMed ID: 39068234
[TBL] [Abstract] [Full Text] [Related]
[Next]
